Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

Pages

1133 results
12:13 PM, Jul 20, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Partial clinical hold on ADC sinks Mersana shares

Mersana Therapeutics Inc. (NASDAQ:MRSN) lost $5.20 (32%) to $11.26 on July 19 after it said FDA placed a partial clinical hold on a Phase I trial of XMT-1522 following a "possibly drug-related" patient death. The...
9:39 AM, Jul 20, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Aveo drops on delay for Phase III tvozanib readout

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) fell $0.69 (24%) to $2.16 on July 17 after delaying for at least the second time an expected readout from a Phase III trial of tivozanib to treat advanced renal cell...
9:27 AM, May 04, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Regeneron halting higher doses in fasinumab trials

about the higher doses or whether the analysis was planned. Fasinumab, a mAb against nerve growth factor
  Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan  Product: Fasinumab  Business: Neurology  Molecular target: Nerve growth factor
NGF)  Description: mAb against nerve growth factor (NGF)  Indication: NA  Endpoint: NA  Status: Phase III amended  Milestone …
11:36 AM, Apr 13, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Alphamab's HER2 bispecific antibody to enter clinic in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) will begin in 3Q18 the dose-escalation portion of a Chinese Phase I trial evaluating KN026 to treat HER2-positive locally advanced and metastatic solid tumors in patients who failed previous...
1:25 PM, Jan 26, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

DSMC recommends continuation of MacroGenics' Phase III of margetuximab to treat breast cancer

MacroGenics Inc. (NASDAQ:MGNX) said an independent DSMC recommended continuation of the Phase III SOPHIA trial of margetuximab (MGAH22) to treat relapsed or refractory HER2-positive metastatic breast cancer based on preplanned interim futility analysis of progression-free...
2:57 PM, Jan 05, 2018  |  BC Week In Review | Clinical News  |  Clinical Status

Deciphera begins Phase III of GIST candidate

small molecule pan-stem cell factor (SCF) receptor tyrosine kinase (c-Kit; KIT; CD117) and platelet derived growth factor
inhibitor. Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH), Waltham, Mass.  Product: DCC-2618  Business: Cancer  Molecular target: Platelet derived growth factor
1:42 PM, Dec 01, 2017  |  BC Week In Review | Clinical News  |  Clinical Status

Regeneron to discontinue nesvacumab/Eylea combo

Eylea is a human fusion protein that binds all forms of VEGF-A and placental growth factor
12:18 PM, Nov 17, 2017  |  BC Week In Review | Clinical News  |  Clinical Status

Chi-Med begins Phase III trial of fruquintinib for gastric cancer

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) began the Phase III FRUTIGA trial of fruquintinib (HMPL-013) as second-line treatment of advanced gastric or gastroesophageal junction cancer in about 544 patients. Patients will receive paclitaxel plus placebo...
12:30 PM, Nov 03, 2017  |  BC Week In Review | Clinical News  |  Clinical Status

Pieris begins Phase I of PRS-343 in solid tumors

Cancer  Molecular target: Tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137); Epidermal growth factor
2:43 PM, Oct 27, 2017  |  BC Week In Review | Clinical News  |  Clinical Status

Aveo continuing Phase III of tivozanib for RCC

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) said an independent statistician recommended continuation of the Phase III TIVO-3 trial of Fotivda tivozanib (ASP4130, AV-951) to treat renal cell carcinoma (RCC) based on a preplanned futility analysis. The open-label,...

Pages